PCM
HZNP

Pyrrho Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Pyrrho Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.52M Buy
93,900
+51,900
+124% +$941K 2.28% 12
2016
Q3 		$761K Buy
+42,000
New +$821K 1.13% 19

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pyrrho Capital Management's HZNP Position: Q4 2016 in Review

Pyrrho Capital Management increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 124% in Q4 2016, buying an estimated $941K and bringing the position to 93,900 shares worth $1.52M. The position accounts for 2.28% of the portfolio, ranked #12.

Pyrrho Capital Management first reported a position in HZNP in Q3 2016 and has held it in 2 quarters since. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

  • Pyrrho Capital Management held 93,900 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $1.52M as of Q4 2016.
  • Pyrrho Capital Management bought 51,900 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $941K.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 2.28% of Pyrrho Capital Management's portfolio in Q4 2016, its #12 holding.
  • Pyrrho Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and has held it in 2 quarters since.
  • 234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on Pyrrho Capital Management's 13F filing for Q4 2016, filed 10 Feb 2017.